Biological Products, (No Diagnostic Substances) · DE · CIK 1357459
Developing targeted oral PDE4 inhibitor prodrugs for inflammatory bowel disease
Comparable business profile · signals at a glance
In the 90 days to Feb 12, 2026: 1 insider bought $18K · 2 sold $10K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 12, 2026 | Finley John DavidCEO, CFO | Sell | 3,896 | $1.75 | $7K |
| Feb 12, 2026 | Jones Mitchell LawrenceChief Medical Officer | Sell | 1,989 | $1.75 | $3K |
| Jan 16, 2026 | Williams Donald AllenDirector | Buy | 5,000 | $1.67 | $8K |
| Jan 9, 2026 | Williams Donald AllenDirector | Buy | 5,000 | $1.88 | $9K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.